EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Erythropoietin and Darbepoetin for Treatment of Anemia in Chronic Kidney Disease Patients: A Comparative Observational Study

Brajesh Kumar, Lalit Kumar, Jeetendra Kumar

International Journal of Current Pharmaceutical Review and Research · 30.07.2026 · 18 (07)

DOI: 10.25258/ijcpr.18.7.62 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.07.2026. Verfasst von Brajesh Kumar und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

One common outcome of chronic kidney disease (CKD) is anemia. Darbepoetin and erythropoietin are the main medications used to treat it. This study compared the safety and effectiveness of darbepoetin against erythropoietin injection for the treatment of renal anemia in patients with chronic kidney disease.

Methods

The study included patients of any gender with hemoglobin levels less than 12 g/dl who were diagnosed with anemia owing to chronic kidney disease (CKD), regardless of dialysis. The laboratory results of hemoglobin (Hb), red blood cells (RBCs), haematocrit (PCV), and adverse events were used to compare the safety and effectiveness of erythropoietin and darbepoetin.

Results

Of the 216 patients who satisfied the inclusion criteria, 108 received erythropoietin treatment and 108 received darbepoetin treatment. In the group of patients receiving erythropoietin, the changes in Hb, RBCs, and PCV were 1.16, 0.49, and 3.76, respectively. Similarly, the group of patients using Darbepoetin showed changes in Hb, RBCs, and PCV of 1.19, 0.42, and 3.52, respectively. The variations in Hb, RBCs, and PCV between the two patient groups were 0.04, 0.07, and 0.24, respectively. 48 (44.44%) patients in the erythropoietin group had four adverse events (HTN, vomiting, headache, and joint pain), while 38 (35.19%) patients in the darbepoetin group reported one adverse event (HTN).

Conclusion

For the treatment of anemia in CKD patients, erythropoietin and darbepoetin were found to be equally safe and efficacious.

Zitieren

APA

Kumar, B., Kumar, L., & Kumar, J. (2026). Efficacy and Safety of Erythropoietin and Darbepoetin for Treatment of Anemia in Chronic Kidney Disease Patients: A Comparative Observational Study. International Journal of Current Pharmaceutical Review and Research, 18(07). https://doi.org/10.25258/ijcpr.18.7.62

Vancouver

Kumar B, Kumar L, Kumar J. Efficacy and Safety of Erythropoietin and Darbepoetin for Treatment of Anemia in Chronic Kidney Disease Patients: A Comparative Observational Study. International Journal of Current Pharmaceutical Review and Research. 2026;18(07). doi:10.25258/ijcpr.18.7.62

BibTeX
@article{Kumar2026,
  author = {Kumar, Brajesh and Kumar, Lalit and Kumar, Jeetendra},
  title = {Efficacy and Safety of Erythropoietin and Darbepoetin for Treatment of Anemia in Chronic Kidney Disease Patients: A Comparative Observational Study},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {07},
  doi = {10.25258/ijcpr.18.7.62}
}
Kostenlos starten →